We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

50 hedge funds and large institutions have $91M invested in Merrimack Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $6.79M | Put options by funds: $3.96M

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

12% more capital invested

Capital invested by funds: $81.2M → $91M (+$9.8M)

6% more funds holding

Funds holding: 47 → 50 (+3)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
50
Holders Change
+3
Holders Change %
+6.38%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
10
Increased
14
Reduced
9
Closed
7
Calls
$6.79M
Puts
$3.96M
Net Calls
+$2.84M
Net Calls Change
-$20K

Top Buyers

Rank Fund Capital Flow
1
MAP
Madison Avenue Partners
New York
+$6.5M
2
Invesco
Invesco
Georgia
+$2.47M
3
WSL
Western Standard LLC
California
+$1.68M
4
NM
Newtyn Management
New York
+$1.24M
5
Marshall Wace
Marshall Wace
United Kingdom
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
2L
22NW LP
Washington
-$11.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.52M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.37M
4
O
OrbiMed
New York
-$843K
5
PVI
Pura Vida Investments
New York
-$735K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
26
Kennedy Capital Management
Missouri
$169K +$162K +13,758 New
Belvedere Trading
27
Belvedere Trading
Illinois
$134K -$330K -28,102 -72%
Citadel Advisors
28
Citadel Advisors
Florida
$104K +$99.8K +8,491 New
Barclays
29
Barclays
United Kingdom
$66.8K +$62.3K +5,303 +3,928%
MWM
30
Mascoma Wealth Management
New Hampshire
$62K – – –
Lazard Asset Management
31
Lazard Asset Management
New York
$60K +$58.2K +4,951 New
UBS Group
32
UBS Group
Switzerland
$38.4K +$27.7K +2,353 +304%
DWA
33
Dorsey Wright & Associates
California
$22.1K +$21.1K +1,799 New
WB
34
Webster Bank
Connecticut
$18.8K – – –
Bank of America
35
Bank of America
North Carolina
$18.3K -$2.19K -186 -11%
NA
36
NewEdge Advisors
Louisiana
$17.3K – – –
TRCT
37
Tower Research Capital (TRC)
New York
$15K -$23.6K -2,007 -62%
DFCM
38
Dark Forest Capital Management
Puerto Rico
$13K +$12.5K +1,060 New
BWP
39
Baldwin Wealth Partners
Massachusetts
$6.14K – – –
Kayne Anderson Rudnick Investment Management
40
Kayne Anderson Rudnick Investment Management
California
$3.69K – – –
SSB
41
Sandy Spring Bank
Maryland
$3.69K – – –
RA
42
Rise Advisors
New York
$3.34K – – –
Wells Fargo
43
Wells Fargo
California
$2.09K +$24 +2 +1%
Fidelity Investments
44
Fidelity Investments
Massachusetts
$2.09K +$2K +170 New
TFGT
45
TS Financial Group (TSFG)
Illinois
$2K – – –
Federated Hermes
46
Federated Hermes
Pennsylvania
$1.11K – – –
HCM
47
Horrell Capital Management
Arkansas
$1K – – –
AAG
48
Armstrong Advisory Group
Massachusetts
$554 – – –
AF
49
Advisornet Financial
Minnesota
$246 – – –
2L
50
22NW LP
Washington
– -$11.6M -1,015,048 Closed
1
2
3

MACK Hedge Fund Activity: Q1 2023 in Review

50 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2023, worth a combined $91M — up 12% from $81.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new MACK positions and 7 closed out — a net gain of 3 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $6.5M. The largest seller was 22NW LP, exiting entirely with an estimated $11.6M sold.

  • 50 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2023, up from 47 in Q4 2022.
  • Funds reported $91M of Merrimack Pharmaceuticals, Inc. stock for Q1 2023, up 12% quarter-over-quarter.
  • 10 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2023 and 7 closed out, a net change of +3 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2023 was Madison Avenue Partners, an estimated $6.5M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2023 was 22NW LP, an estimated $11.6M sold.

Based on aggregated 13F filings for Q1 2023.